AITX's RAD Dominates ISC West with Major Awards and Surge in Enterprise Leads
RAD Secures Over 300 Qualified Leads at ISC West 2025
Detroit, Michigan--(Newsfile Corp. - April 7, 2025) - Robotic Assistance Devices, Inc. (RAD), a subsidiary of Artificial Intelligence Technology Solutions, Inc. (OTC Pink: AITX) (the 'Company'), achieved a major milestone at ISC West 2025, the premier event for security professionals. RAD earned both the Best in Threat Detection and Response Solutions award and the prestigious Judges' Choice Award at the SIA New Product Showcase, with its SARA ™ (Speaking Autonomous Responsive Agent) recognized as the standout innovation of the entire show.
Steve Reinharz, CEO/CTO of AITX and RAD, holds the SIA Judges' Choice Award earned by SARA, the AI Security Agent, during ISC West 2025, presented in the SARA Experience Zone at the RAD booth.
To view an enhanced version of this graphic, please visit:
These accolades reflect RAD's continued leadership in redefining physical security through artificial intelligence, robotics, and automation.
Beyond the awards, RAD connected with over 300 new prospects at the event, each verified and requesting follow-up. Nearly 50 of these prospects represent Fortune 1000 organizations, including six Fortune 50 companies not currently doing business with RAD. The volume and caliber of interest signal a rapid expansion of RAD's visibility and appeal across enterprise and institutional markets.
Widespread Industry Engagement
RAD's powerful lineup of solutions, including ROAMEO ™, RIO ™, AVA ™, SARA, ROSA ™, and its Firearm Detection analytic, sparked compelling conversations across numerous sectors:
Enterprise & Corporate Facilities: Multiple global organizations expressed strong interest in RAD's ability to automate perimeter patrols, improve visitor access control, and streamline monitoring operations through AI-driven systems.
Government & Scientific Institutions: Organizations overseeing critical infrastructure and space operations identified RAD's autonomous units as effective tools for safeguarding high-value assets and enhancing situational awareness.
Healthcare Networks: Several leading healthcare systems prioritized RAD's solutions for securing hospital exteriors and parking areas, with urgent deployment requests for ROAMEO, RIO and RAD Light My Way ™.
Logistics & Transportation: Major providers initiated RFP discussions focused on modernizing entry and exit operations, aiming to reduce reliance on manned guard stations by deploying RAD's integrated platforms.
Retail & Commercial Properties: Large retail chains outlined plans to replace parking lot guards with autonomous patrol units, citing RAD's effectiveness in enhancing deterrence and improving overall safety.
Aerospace & Defense: Operators of secure facilities and industrial campuses evaluated ROAMEO and RIO for deployment in perimeter and parking zone protection, recognizing the value of autonomous coverage in high-security environments.
Entertainment & Venues: Event venues and stadiums prioritized rapid integration of RAD solutions, including Security Operations Center (SOC) enhancements with SARA and active on-site deterrence using RIO and ROAMEO.
Market Trends Confirm RAD's Direction
Conversations throughout the event reinforced RAD's position at the forefront of security innovation, with recurring themes including:
Guard Force Reduction: Organizations are actively shifting toward automation to reduce dependency on traditional guard services and improve operational efficiency.
Parking & Perimeter Safety: Interest in ROAMEO and RIO continues to grow as organizations look to secure expansive, high-risk areas with solutions that offer consistent coverage and active deterrence.
AI-Driven Security Monitoring: Organizations are increasingly prioritizing real-time analytics and proactive, intelligent alerting as essential components of modern security strategies.
'Winning both our category and the overall Judges' Choice Award at ISC West is an extraordinary honor,' said Steve Reinharz, CEO/CTO of AITX and RAD. 'But what excites us even more is the overwhelming response from top-tier companies and institutions that see RAD as the future of security and automation.'
AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the nearly $50 billion (US) security and guarding services industry i through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers these tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.
RAD has a prospective sales pipeline of over 35 Fortune 500 companies and numerous other client opportunities. RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream. Each Fortune 500 client has the potential of making numerous reorders over time.
About Artificial Intelligence Technology Solutions (AITX)
AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-R, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit www.aitx.ai, www.radsecurity.com, www.stevereinharz.com, www.radgroup.ai, www.raddog.ai, and www.radlightmyway.com, or follow Steve Reinharz on Twitter @SteveReinharz.
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the 'Company'). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
Steve Reinharz
949-636-7060
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Lifordi Immunotherapeutics Presents Preclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 to Treat Autoimmune and Inflammatory Diseases at EULAR 2025
Burlington, Massachusetts--(Newsfile Corp. - June 11, 2025) - Lifordi Immunotherapeutics, Inc., a biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, presented preclinical data on its lead program for LFD-200, an ADC delivering a potent glucocorticoid (GC) directly to immune cells. Results of multiple in vitro and in vivo studies in mice and in non-human primates (NHPs) demonstrated that LFD-200 achieves targeted and sustained delivery of its GC payload to immune cells, resulting in efficacy without systemic toxicity. These data were presented at the European Alliance of Associations for Rheumatology (EULAR) meeting in Barcelona. To view the full announcement, including downloadable images, bios, and more, click here. Click image above to view full announcement. About Lifordi Lifordi Immunotherapeutics, Inc. is leading the way in leveraging the success of antibody-drug conjugates (ADCs) to develop treatments for autoimmune and inflammatory disorders. The Company's lead ADC, LFD-200, has demonstrated efficacy in multiple preclinical disease models by targeting myeloid and lymphoid cells using a highly internalized cell surface membrane protein (VISTA). Lifordi has also applied its novel drug delivery platform to other diverse payloads, such as small molecules, antisense oligonucleotides (ASOs) and siRNA. As experienced drug developers in immunology and inflammatory diseases, together with expert clinical advisors, a strong partnering track record, and funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture to support initial clinical data, Lifordi is committed to changing how immune and inflammatory diseases are treated. For more information, please visit Contacts: Theresa McNeely tmcneely@ Source: Lifordi To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
CEO.CA's Inside the Boardroom: Mandalay Resources CEO: "This is Just the Beginning" After Beating Q1 & Announcing Merger
Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - (" the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers. Founded in 2012, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality. Millions of people visit each year to connect with investors from around the world, share knowledge and view impactful stories about stocks, commodities, and emerging companies. Meet the Executive Shaping the Mining Landscape 'Inside the Boardroom' is more than just an interview series - it's a chance to gain firsthand knowledge from industry leaders, understanding their vision, challenges, and strategy. We invited Frazer Bourchier, President & CEO of Mandalay Resources Corp. (TSX: MND) (OTCQB: MNDJF) to talk to us about the company's rationale for a recently announced merger with Alkane Resources. We also discuss Mandalay's impressive revenue growth and large cash position, and what the company plans to do with capital allocation. Mandalay Resources(TSX: MND) (OTCQB: MNDJF) Cannot view this video? Visit: Tune in to 'Inside the Boardroom' each week and be part of the conversation that's shaping the business landscape. Visit or our YouTube page for hundreds more executive interviews from here. Interested in showcasing your company on 'Inside the Boardroom'? Get in touch with our team at sales@ for further details and opportunities. About The leading community for investors & traders in junior resource & venture stocks. is one of the most popular free financial websites and apps in Canada and for small-cap investors globally -- with industry leading audience engagement and mobile functionality. Since 2012, has brought millions of investors together from over 164 countries to discuss their portfolio holdings and find new investment opportunities. Download our App on iOS or Android marketplace or visit us today at to set up your free account. is a wholly owned subsidiary of EarthLabs, Inc. For further information please contact: Email: hello@ Neither the TSX Venture Exchange ("TSXV"), OTC Best Market "(OTCQX") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement The information regarding any issuer contained or referred to in any interviews conducted by has been furnished by such issuer directly, and neither nor any of its affiliates or principals assumes any responsibility for the accuracy or completeness of such information or for any failure by an issuer to ensure disclosure of events or facts which may affect the significance or accuracy of any such information. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release may include, but is not limited to, the objectives, goals, future plans, statements regarding exploration results and exploration and/or development plans of companies featured on the platform. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects, currency risk and the other risks involved in the applicable exploration and development industry, and those risks set out in the public documents of such companies filed on SEDAR or elsewhere from time to time. Undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
CBD Life Sciences Inc. (CBDL) Reports 1,502.30% Revenue Increase from January to May 2025
Achieving a five-month revenue growth equivalent to an annualized rate exceeding 4,000%, as the booming CBD and mushroom supplement markets-projected to reach $30 billion and $15 billion respectively by 2028-fuel strong consumer demand and industry expansion. SCOTTSDALE, AZ / / June 11, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a rising player in the natural health and wellness space, is proud to report a 1,502.30% increase in revenue from January through May of 2025 - a historic milestone for the company and a clear reflection of its expanding presence across retail, digital, and direct-to-consumer channels. This performance marks the company's strongest run of sustained month-over-month revenue growth to date and comes as CBDL shifts from a single-category CBD company to a diversified wellness brand with products designed for modern performance, recovery, and cognitive support. "This isn't just about selling more products - it's about becoming a health brand that consumers actively seek out," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "We've laid the foundation for scalable, repeatable success by combining innovation, access, and a strong identity in functional wellness." Key Drivers Of Growth National Retail Expansion & E-Commerce UbiquityCBDL's ability to meet consumers where they shop has been a major growth catalyst in 2025. The brand has successfully launched and scaled across high-traffic digital and physical platforms, including: Walmart Marketplace: Multiple SKUs now available online, including CBDL's best-selling 3000MG Pain Relief Cream and skin care formulations. DoorDash & Leafly: Products are accessible via local delivery in select markets, offering speed and convenience for customers. Groupon: Strategic limited-time wellness deals driving strong first-time purchase activity and consumer discovery. Shopify & Reddit: Expanded direct-to-consumer operations through Shopify, complemented by engagement in Reddit's niche wellness communities to boost brand awareness and customer acquisition. Product Innovation: Functional Wellness for the Modern Consumer CBDL's revenue growth closely aligns with its rapid innovation across plant-powered health categories. Beyond CBD, the company is gaining traction with functional and adaptogenic wellness products, including: Mushroom Smoothies & Brain Support Blends: Featuring natural cognitive enhancers like lion's mane, reishi, and cordyceps, these smoothies support memory, mental clarity, and energy - and are appearing in local coffee shops and health stores. Power+ Sexual Enhancement Supplement: A plant-based formula supporting male vitality, stamina, and circulation, quickly becoming a customer favorite. Adaptogenic Mushroom Supplements: Proprietary blends designed to support immune health, stress reduction, and overall daily balance, harnessing reishi, chaga, lion's mane, and ashwagandha. Strategic Vision & Responsible Growth CBDL continues to invest in infrastructure, brand visibility, and strategic partnerships to ensure long-term sustainable growth. While focusing on the U.S. market currently, the company is evaluating future expansion opportunities and additional retail collaborations. "Our focus remains on delivering real value through trusted products and accessible retail channels," added Nelson. "We are committed to building a wellness brand that serves consumers authentically while creating shareholder value." About CBD Life Sciences Inc. (CBDL) CBD Life Sciences Inc. is an Arizona-based health and wellness company focused on premium CBD, adaptogenic, and mushroom-based wellness products designed to support modern lifestyles. From pain relief to cognitive support and men's health, CBDL is committed to transparency, innovation, and accessibility. Follow our social media for the latest updates!X: Contact: cbdvaultaz@ Stay Connected & Be the First to Try Our New Functional Mushroom Products! Mushroom Madness Instagram: Madness Website: Forward-Looking StatementsExcept for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Safe Harbor StatementThis release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements. Contact InformationLisa NelsonCEOcbdvaultaz@ SOURCE: CBD Life Sciences Inc. View the original press release on ACCESS Newswire
